Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.
2.

Selection of cell lines with enhanced invasive phenotype from xenografts of the human prostate cancer cell line WPE1-NB26.

Rivette AS, Tokar EJ, Williams DE, Mackenzie CD, Ablin RJ, Webber MM.

J Exp Ther Oncol. 2005;5(2):111-23.

PMID:
16471037
3.

Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression.

Webber MM, Quader ST, Kleinman HK, Bello-DeOcampo D, Storto PD, Bice G, DeMendonca-Calaca W, Williams DE.

Prostate. 2001 Apr;47(1):1-13.

PMID:
11304724
4.

The role of alpha 6 beta 1 integrin and EGF in normal and malignant acinar morphogenesis of human prostatic epithelial cells.

Bello-DeOcampo D, Kleinman HK, Webber MM.

Mutat Res. 2001 Sep 1;480-481:209-17.

PMID:
11506815
5.

A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide.

Hu DG, Gardner-Stephen D, Severi G, Gregory PA, Treloar J, Giles GG, English DR, Hopper JL, Tilley WD, Mackenzie PI.

Mol Pharmacol. 2010 Oct;78(4):714-22. doi: 10.1124/mol.110.065953.

6.

Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression.

Pâquet S, Fazli L, Grosse L, Verreault M, Têtu B, Rennie PS, Bélanger A, Barbier O.

J Clin Endocrinol Metab. 2012 Mar;97(3):E428-32. doi: 10.1210/jc.2011-2064.

PMID:
22170718
7.

Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression.

Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, Yang H, Varma VA, Sun QC, Petros JA, Lim SD, Amin MB.

Gene. 2001 Nov 14;279(1):17-31.

PMID:
11722842
8.

Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution.

Gauthier-Landry L, Bélanger A, Barbier O.

J Steroid Biochem Mol Biol. 2015 Jan;145:187-92. doi: 10.1016/j.jsbmb.2014.05.009. Review.

PMID:
24861263
9.

Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.

Mimeault M, Johansson SL, Henichart JP, Depreux P, Batra SK.

Mol Cancer Ther. 2010 Mar;9(3):617-30. doi: 10.1158/1535-7163.MCT-09-1013.

10.

Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells.

Kaeding J, Bouchaert E, Bélanger J, Caron P, Chouinard S, Verreault M, Larouche O, Pelletier G, Staels B, Bélanger A, Barbier O.

Biochem J. 2008 Mar 1;410(2):245-53.

PMID:
17988216
11.

Evaluation of the chemopreventive potential of retinoids using a novel in vitro human prostate carcinogenesis model.

Quader ST, Bello-DeOcampo D, Williams DE, Kleinman HK, Webber MM.

Mutat Res. 2001 Sep 20;496(1-2):153-61.

PMID:
11551491
12.

Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.

Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV.

Cell Cycle. 2006 Aug;5(16):1886-901.

PMID:
16963837
13.

Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk.

Park JY, Tanner JP, Sellers TA, Huang Y, Stevens CK, Dossett N, Shankar RA, Zachariah B, Heysek R, Pow-Sang J.

Urology. 2007 Aug;70(2):374-9.

PMID:
17826523
15.

Extracellular redox state regulates features associated with prostate cancer cell invasion.

Chaiswing L, Zhong W, Cullen JJ, Oberley LW, Oberley TD.

Cancer Res. 2008 Jul 15;68(14):5820-6. doi: 10.1158/0008-5472.CAN-08-0162.

16.

Novel human prostate epithelial cell culture models for the study of carcinogenesis and of normal stem cells and cancer stem cells.

Rhim JS, Li H, Furusato B.

Adv Exp Med Biol. 2011;720:71-80. doi: 10.1007/978-1-4614-0254-1_6. Review.

PMID:
21901619
17.

Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target.

Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, Wong YC, Wang X.

Cancer Res. 2005 Jun 15;65(12):5153-62.

18.

Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer.

Escara-Wilke J, Keller JM, Ignatoski KM, Dai J, Shelley G, Mizokami A, Zhang J, Yeung ML, Yeung KC, Keller ET.

Prostate. 2015 Feb 15;75(3):292-302. doi: 10.1002/pros.22915.

20.

Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells.

Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, Kamer I, Stambolsky P, Shelly A, Goldfinger N, Valsesia-Wittmann S, Puisieux A, Zundelevich A, Gal-Yam EN, Avivi C, Barshack I, Brait M, Sidransky D, Domany E, Rotter V.

Cell Death Differ. 2011 Feb;18(2):271-81. doi: 10.1038/cdd.2010.94.

Items per page

Supplemental Content

Support Center